Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases. The company also develops NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1, a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and PX-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and rheumatoid arthritis. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia.
IPO Year: 2021
Exchange: NASDAQ
Website: landosbiopharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/12/2022 | $30.00 → $1.40 | Buy → Hold | Jefferies |
| 1/3/2022 | $15.00 → $7.00 | Neutral | JP Morgan |
| 11/16/2021 | $20.00 → $16.00 | Outperform → Market Perform | SVB Leerink |
| 10/20/2021 | $45.00 | Buy | Craig-Hallum |
| 10/19/2021 | $50.00 | Buy | HC Wainwright & Co. |
| 9/23/2021 | $39.00 | Buy | JonesTrading |
| 7/30/2021 | $33.00 → $35.00 | Outperform | Raymond James |
- Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD) NORTH CHICAGO, Ill., May 23, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced today that it has completed its acquisition of Landos Biopharma, Inc. (NASDAQ:LABP). With the completion of the acquisition, Landos is now part of AbbVie. Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family), which is currently in Phase 2 for the treatment of moderate to severe UC (NEXUS study; NCT05785715). NLRX1 regulates immunometabolism and inflammation,
MILWAUKEE, April 16, 2024 /PRNewswire/ -- Ademi LLP investigation of Landos (NASDAQ:LABP) continues now that Landos has filed a preliminary proxy statement seeking stockholder approval for its transaction with AbbVie. Click here to learn how to join the https://www.ademilaw.com/case/landos-biopharma-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. In the transaction, Landos shareholders will receive only $20.42 per share in cash upon closing, or approximately $137.5 million in the aggregate, plus one non-tradable contingent value right
Landos' lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC)NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) ("AbbVie") and Landos Biopharma, Inc. (NASDAQ:LABP) ("Landos") today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases. Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action (MOA), which is anti-inflammatory and facilitates
NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- AbbVie Inc. (NYSE:ABBV) ("AbbVie") and Landos Biopharma, Inc. (NASDAQ:LABP) ("Landos") today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases. Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action (MOA), which is anti-inflammatory and facilitates epithelial repair. "With this acquisition, we aim to advance the clinical development of NX-13, a differentiated, f
Top-line Results from the NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into mid-2025 NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP) ("Landos" or "the Company"), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and reported financial results for the fourth quarter and the full year ended December 31, 2023. "We were focused in 2023 on advancing the NX-13 clinical program and establishing Landos as a leader in targeting immunometabolic pathways and de
NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP) ("Landos" or the "Company"), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that six abstracts were accepted for poster presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation (ECCO). The abstracts highlight new and additional data on immunometabolism modulation by activating NLRX1 and PLXDC2 with novel agonists such as NX-13 and LABP-69. The ECCO congress will take place February 21-24, 2024 in Stockholm, Sweden. "Immunometabolic targets work to restrict entry into the inflammatory cascade to
NX-13, a Novel, Oral, NLRX1 Agonist, was Observed to be Well Tolerated and Demonstrated Early Signs of Rapid Symptomatic Relief and Endoscopic Improvement in Patients with Ulcerative Colitis NEXUS Phase 2 Proof-of-Concept Study is Ongoing, with Top-Line Readout Expected in Q4 2024 NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced a peer-reviewed publication describing the safety, tolerability, pharmacokinetic and clinical efficacy results for the NX-13 Phase 1b trial in patients with ulcerative colitis (UC) in the Journal
NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Remains On Track with Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the quarter ended September 30, 2023. "The NX-13 Phase 2 clinical program (NEXUS) remains our top priority, and we are pleased with our execution and progress during the third quarter," said Gregory Oakes, President and CEO of Lan
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it will present additional findings from its Phase 1b study of NX-13 for the treatment of ulcerative colitis (UC), including detailed results on the rapid symptomatic relief and improvement in multiple clinical biomarkers observed in the study, at the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting, being held October 20-25 in Vancouver, Canada. "We are excited for the opportunity to present at a premier gastroenterology event like ACG and share add
NX-13 Demonstrated Rapid Symptomatic Relief and Improvement in Multiple Biomarkers that Correlated With Early Endoscopic Response in Patients With Ulcerative Colitis (UC) NEXUS Phase 2 Clinical Trial is Ongoing; Top-line Readout Expected in Q4 2024 NEW YORK, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced presentation of new data on the rapid symptomatic relief and improvement in multiple clinical biomarkers observed with NX-13 in its Phase 1b study in UC at the upcoming UEG Week 2023 congress in Copenhagen, Denmark and virtually fro
4 - Landos Biopharma, Inc. (0001785345) (Issuer)
4 - Landos Biopharma, Inc. (0001785345) (Issuer)
4 - Landos Biopharma, Inc. (0001785345) (Issuer)
4 - Landos Biopharma, Inc. (0001785345) (Issuer)
4 - Landos Biopharma, Inc. (0001785345) (Issuer)
4 - Landos Biopharma, Inc. (0001785345) (Issuer)
4 - Landos Biopharma, Inc. (0001785345) (Issuer)
4 - Landos Biopharma, Inc. (0001785345) (Issuer)
4 - Landos Biopharma, Inc. (0001785345) (Issuer)
4 - Landos Biopharma, Inc. (0001785345) (Issuer)
Jefferies downgraded Landos Biopharma from Buy to Hold and set a new price target of $1.40 from $30.00 previously
JP Morgan reiterated coverage of Landos Biopharma with a rating of Neutral and set a new price target of $7.00 from $15.00 previously
SVB Leerink downgraded Landos Biopharma from Outperform to Market Perform and set a new price target of $16.00 from $20.00 previously
Craig-Hallum initiated coverage of Landos Biopharma with a rating of Buy and set a new price target of $45.00
HC Wainwright & Co. initiated coverage of Landos Biopharma with a rating of Buy and set a new price target of $50.00
JonesTrading initiated coverage of Landos Biopharma with a rating of Buy and set a new price target of $39.00
Raymond James reiterated coverage of Landos Biopharma with a rating of Outperform and set a new price target of $35.00 from $33.00 previously
SVB Leerink initiated coverage of Landos Biopharma with a rating of Outperform and set a new price target of $20.00
Raymond James resumed coverage of Landos Biopharma with a rating of Outperform and set a new price target of $33.00
Jefferies Financial Group initiated coverage of Landos Biopharma with a rating of Buy and set a new price target of $32.00
Advancing NX-13 Clinical Development for Treatment of Ulcerative Colitis On Track to Initiate Phase 2 Proof-of-Concept Trial for NX-13 in the Second Quarter of 2023 and Report Topline Data by the Fourth Quarter of 2024 Broader, Novel Pipeline Poised for Partnering and Continued Development in the Future; Significant Optionality for Omilancor, LABP-104 and Four Promising Pre-Clinical Programs Secures Additional $16.7 Million Investment Disciplined Financial Approach Expected to Maintain Cash Runway into First Half of 2025 Company to Host Investor Call at 8:00 AM ET NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP) ("Landos" or the "Company"), a clinical
Enhancing Focus on High-Impact Clinical-Stage Programs to Ensure Optimal Path to Commercialization Refining Ulcerative Colitis Clinical Development Plans for Omilancor to Generate Additional Phase 2b Data Prior to Initiating Pivotal Phase 3 Program Determining Optimal Enrollment for Phase 2 Clinical Study of Omilancor in Crohn's Disease and Phase 1b Study of NX-13 in UC Initiated Dosing for LABP-104 in Healthy Volunteers in October 2021 with Results Expected in 1H 2022 Corporate Update Conference Call Scheduled for 8:00 am ET Today BLACKSBURG, Va., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a clin
BLACKSBURG, Va., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma Inc. (NASDAQ:LABP) today announced that it will report third quarter 2021 financial results and host a conference call to provide a corporate update on November 15, 2021. Following the release of the financial results, Landos will host a live webcast at 8:00 am ET. The webcast can be accessed through the Company's investor relations website at https://ir.landosbiopharma.com/, or by dialing 1-877-317-6789 (Toll Free) or 1-412-317-6789 (International) and asking to join the Landos Corporate Update call. The webcast will be archived and be available for replay on the Company's investor relations website. About Landos Biopha
SC 13D/A - Landos Biopharma, Inc. (0001785345) (Subject)
SC 13D/A - Landos Biopharma, Inc. (0001785345) (Subject)
SC 13G/A - Landos Biopharma, Inc. (0001785345) (Subject)
SC 13D/A - Landos Biopharma, Inc. (0001785345) (Subject)
SC 13D/A - Landos Biopharma, Inc. (0001785345) (Subject)
SC 13G/A - Landos Biopharma, Inc. (0001785345) (Subject)
SC 13D/A - Landos Biopharma, Inc. (0001785345) (Subject)
SC 13D/A - Landos Biopharma, Inc. (0001785345) (Subject)
SC 13D/A - Landos Biopharma, Inc. (0001785345) (Subject)
SC 13D/A - Landos Biopharma, Inc. (0001785345) (Subject)
15-12G - Landos Biopharma, Inc. (0001785345) (Filer)
RW - Landos Biopharma, Inc. (0001785345) (Filer)
S-8 POS - Landos Biopharma, Inc. (0001785345) (Filer)
S-8 POS - Landos Biopharma, Inc. (0001785345) (Filer)
S-8 POS - Landos Biopharma, Inc. (0001785345) (Filer)
S-8 POS - Landos Biopharma, Inc. (0001785345) (Filer)
25-NSE - Landos Biopharma, Inc. (0001785345) (Subject)
8-K - Landos Biopharma, Inc. (0001785345) (Filer)
10-Q - Landos Biopharma, Inc. (0001785345) (Filer)
DEFM14A - Landos Biopharma, Inc. (0001785345) (Filer)
Friday, AbbVie Inc (NYSE:ABBV) reported first-quarter adjusted EPS of $2.31, down 6.1% Y/Y, beating the consensus of $2.23. Net revenues reached $12.31 billion, up 0.7%, beating the consensus of $11.92 billion. Sales were up 1.6% on an operational basis. “First quarter results were well ahead of our expectations, driven by excellent performance from our ex-Humira growth platform,” said Robert Michael, president and chief operating officer. The immunology portfolio generated $5.37 billion in sales, down 3.9% on a reported basis or 3.1% on an operational basis, due to Humira biosimilar competition. Humira revenues were $2.27 billion (down 35.9%), Skyrizi sales reached $2.01 billion
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Landos Biopharma (NASDAQ:LABP) from Buy to Neutral and lowers the price target from $50 to $20.42.
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning higher on Monday. The Dow traded down 0.37% to 39,331.42 while the NASDAQ rose 0.06% to 16,439.38. The S&P 500 also fell, dropping, 0.12% to 5,227.95. Check This Out: Progress Software Likely To Report Lower Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts Leading and Lagging Sectors Energy shares jumped by 1% on Monday. In trading on Monday, industrials shares fell by 0.5%. Top Headline Sales of new single-family houses in the U.S. fell by 0.3% from the prior month to an annualized rate of 662,000 in February, compared to market estimates of 67
Shares of Landos Biopharma, Inc. (NASDAQ:LABP) rose sharply during Monday’s session following acquisition news. AbbVie Inc. (NYSE:ABBV) and Landos Biopharma, reported a definitive agreement under which AbbVie will acquire Landos. Landos Biopharma shares jumped 171.2% to $21.70 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Next.e.GO N.V. (NASDAQ:EGOX) shares jumped 85.8% to $0.0730 after falling around 22% on Friday. Altamira Therapeutics Ltd. (NASDAQ:CYTO) shares climbed 70.1% to $2.9255 after the company announced a collaboration with Univercells Group on nanoparticle-delivered mRNA vaccines. MicroAlgo Inc. (NASDAQ:MLGO) climbed 34.3% to $5.40 a
Gainers Landos Biopharma (NASDAQ:LABP) shares rose 173.9% to $21.45 during Monday's regular session. The market value of their outstanding shares is at $66.8 million. The company's, Q4 earnings came out 2 days ago. Altamira Therapeutics (NASDAQ:CYTO) stock moved upwards by 30.63% to $2.26. The market value of their outstanding shares is at $4.1 million. XTL Biopharmaceuticals (NASDAQ:XTLB) shares increased by 28.24% to $3.36. The company's market cap stands at $18.3 million. Nkarta (NASDAQ:NKTX) shares moved upwards by 23.87% to $11.05. The company's market cap stands at $542.2 million. As per the news, the Q4 earnings report came out 2 days ago. Sagimet Biosciences (NASDAQ:SGMT) stock
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Monday. The Dow traded down 0.22% to 39,389.17 while the NASDAQ fell 0.15% to 16,410.10. The S&P 500 also fell, dropping, 0.16% to 5,226.01. Check This Out: Progress Software Likely To Report Lower Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts Leading and Lagging Sectors Energy shares jumped by 1% on Monday. In trading on Monday, communication services shares fell by 0.5%. Top Headline Sales of new single-family houses in the U.S. fell by 0.3% from the prior month to an annualized rate of 662,000 in February, compared to m
Monday, AbbVie Inc (NYSE:ABBV) agreed to acquire Landos Biopharma Inc (NASDAQ:LABP) for $20.42 per share, or approximately $137.5 million in the aggregate, plus one contingent value right per share with a value of up to $11.14 per share, or approximately an additional $75 million. The proposed transaction is expected to close in the second calendar quarter of 2024. Landos’ lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action (MOA), anti-inflammatory, and facilitates epithelial repair. “With this acquisition, we aim to advance the clinical development of NX-13, a differentiated, first-i
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 50 points on Monday. Following the market opening Monday, the Dow traded down 0.16% to 39,412.36 while the NASDAQ fell 0.42% to 16,359.31. The S&P 500 also fell, dropping, 0.23% to 5,222.33. Check This Out: Progress Software Likely To Report Lower Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts Leading and Lagging Sectors Energy shares jumped by 1.3% on Monday. In trading on Monday, information technology shares fell by 0.7%. Top Headline The Chicago Fed National Activity Index rose to a three-month high level of 0.05 in February versus a revised r
Gainers Landos Biopharma (NASDAQ:LABP) shares moved upwards by 181.6% to $22.05 during Monday's pre-market session. The market value of their outstanding shares is at $68.7 million. As per the press release, Q4 earnings came out 2 days ago. Altamira Therapeutics (NASDAQ:CYTO) shares rose 49.71% to $2.59. The market value of their outstanding shares is at $4.7 million. Esperion Therapeutics (NASDAQ:ESPR) stock increased by 21.83% to $2.79. The company's market cap stands at $516.2 million. Salarius Pharmaceuticals (NASDAQ:SLRX) shares moved upwards by 21.66% to $0.75. The company's market cap stands at $2.9 million. As per the news, the Q4 earnings report came out yesterday. Neuronetics
MILWAUKEE, April 16, 2024 /PRNewswire/ -- Ademi LLP investigation of Landos (NASDAQ:LABP) continues now that Landos has filed a preliminary proxy statement seeking stockholder approval for its transaction with AbbVie. Click here to learn how to join the https://www.ademilaw.com/case/landos-biopharma-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. In the transaction, Landos shareholders will receive only $20.42 per share in cash upon closing, or approximately $137.5 million in the aggregate, plus one non-tradable contingent value right
Initiated NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis NEXUS Remains On Track With Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the second quarter ended June 30, 2023. "We continued to advance and execute the NX-13 Phase 2 clinical program (NEXUS) during the second quarter. We have activated sites in the US and are actively recruiting and screening pa
NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the appointment of Alka Batycky, Ph.D. to its Board of Directors and Audit Committee. "Dr. Batycky is an accomplished biopharmaceutical executive and an important addition to Landos' Board," said Gregory Oakes, President and CEO of Landos. "Dr. Batycky has a proven track record, and we look forward to her contributions as we execute upon our focused strategy in immunology." Dr. Batycky brings with her over 25 years of global drug development experience in the biopharmaceutical in
NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the appointment of Fabio Cataldi, MD, as the Company's Chief Medical Officer, effective September 5, 2022. "We are thrilled to welcome Fabio to Landos, and look forward to benefitting from his extensive clinical and drug development experience as we finalize our portfolio review and execute a focused plan to pursue what we believe are the Company's most promising molecules and target indications," said Greg Oakes, President and Chief Executive Officer of Landos. "Fabio's clinica
BLACKSBURG, Va., March 10, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it has appointed Roger Adsett to the Company's Board of Directors, effective March 8, 2022. Mr. Adsett will serve on the Audit Committee of the Board. With the addition of Mr. Adsett, the Landos Board has been expanded to six members. Mr. Adsett is a healthcare industry veteran with almost thirty years of experience and a proven track record of successful development and commercialization of innovative medicines at several biopharmaceutical companies including Insmed
Josep Bassaganya-Riera Steps Down as Chairman, President and CEO Tim M. Mayleben Appointed Interim President and CEO Chris Garabedian Appointed Chairman of the Board BLACKSBURG, Va., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma Inc. (NASDAQ:LABP), a clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and develop novel oral small-molecule therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Ph.D., has stepped down as Chairman, President and Chief Executive Officer, effective immediately. Tim M. Mayleben, a member of the Landos Board, has been appointed Interim President and CEO. Chris Gar
BLACKSBURG, Va., May 19, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc (NASDAQ:LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the appointment of Tim M. Mayleben to its Board of Directors. Mr. Mayleben joins Landos with more than 20 years of executive experience leading development activities as well as successfully spearheading clinical and business strategies within the life sciences industry. "We are pleased to introduce Tim as the newest Board member, Compensation Committee Chair and member of the Audit Committee," commented Josep Bassaganya-Riera, Chairman, President and
BLACKSBURG, Va., April 13, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (NASDAQ:LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the appointment of Tiago Girão to its Board of Directors. Mr. Girão holds over 20 years of experience as a cross-functional leader who has held various positions in finance and operations for U.S. and global private and public life sciences companies. "We are pleased to welcome Tiago to Landos' Board as the Chair of the Audit Committee, as his wealth of expertise managing strategic planning in finance and operations will provide an invaluable perspecti